You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.
  • References


  1. Trullas-Vila JC et al, Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients, J Thromb Thrombolysis. 2009 Nov;28(4):436-43.
  2. Lengyel M; SPORTIF-III Altanulmány Vizsgálói, Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?, Orv Hetil. 2004 Dec 26;145(52):2619-21.
  3. Neill EC, Moon RY and Veer JBV, Clinical evaluation of a new oral anticoagulant “Sintrom”, Circulation, 1957; 15: 713-20.
  4. Weitz JI. In: Brunton LL (ed). Goodman and Gilman's The pharmacological basis of Therapeutics, 12th edition, New York, Mcgraw Hill, 2011:849-876.
  5. Bennett PN and Brown MJ, Clinical Pharmacology, 9th edition, Edinburgh, Churchill Livingstone, 2003: 568-73.
  6. Ansell J et al, Pharmacology and management of vitamin K antagonists: American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition), Chest 2008;133;160S-198S.
  7. Nahar et al., Int J Genomic Med 2013, 1:1. Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant therapy.
  8. Kulo A, Kusturica J, Kapic E, et al. Better stability of acenocoumarol compared to warfarin treatment in one-year observational, clinical study in patients with non- valvular atrial fibrillation. Med Glas Ljek komore Zenicko-doboj kantona. 2011;8:9–14.
  9. Ufer M, Comparative pharmacokinetics of vitamin K antagonists warfarin, phenprocoumon and acenocoumarol, Clin Pharmacokin 2005; 44(12): 1227-46.
  10. Hemker HC and Frank HLL, The Mechanism of Action of Oral Anticoagulants and Its Consequences For the Practice of Oral Anticoagulation, Haemostasis 1985; 5: 263-270.
  11. Cranenburg ECM, Schurgers LJ and Vermeer C, Vitamin K: The coagulation vitamin that became omnipotent, Thromb Haemost 2007; 98: 120–125.
  12. Wardrop D and Keeling D, The story of the discovery of heparin and warfarin, Br J Haematol, 2008; 141: 757-63.
  13. Brafield AJ, Nicoumalone: A new anticoagulant, Br Med J, 1959; 1: 1211-13.
  14. Sir Dollery C (ed), Therapeutic Drugs, Vol 2, Edinburgh, Churchill Livingstone, 1991: N77-N80.
  15. Meinertz T et al, Anticoagulant activity of the enantiomers of acenocoumarol, Br J Clin Pharmacol 1978; 5: 187-88.
  16. Thijssen HH and Baars LG, Active metabolites of acenocoumarol: Do they contribute to the therapeutic effect? Br J Clin Pharmacol. 1983;16:491-6.
  18. Ufer M, Comparative pharmacokinetics of vitamin K antagonists warfarin, phenprocoumon and acenocoumarol, Clin Pharmacokin 2005; 44(12): 1227-46.
  19. (Accessed on 22nd January 2016).
  20. Gschwind Rollason V, Lovis C, Boehlen F, Bonnabry P, Dayer P, Desmeules JA. Eur J Clin Pharmacol DOI 10.1007/s00228-012-1358-7.
  21. Arboix M, Frati ME, Laporte JR. The potentiation of acenocoumarol anticoagulant effect by amiodarone. Br J Clin Pharmacol. 1984 Sep;18(3):355-60.
  22. Sunkara G, Bigler H, Wang Y, Smith H, Prasad P, McLeod J, Ligueros-Saylan M. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Curr Med Res Opin. 2004 Jan;20(1):41-8.
  23. Rolan P, Terpstra IJ, Clarke C, Mullins F, Visser JN. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol. Br J Clin Pharmacol. 2003; 55(3):314-6.
  24. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004; 24 (2).
  25. Soto J, Sacristan JA, Alsar MJ, Fernandez-Viadero C, Verduga R. Probable acenocoumarol-amoxycillin interaction. Acta Haematol. 1993;90(4):195-7.
  26. Welzen MEB, Berk G, Hamers RL, Burger DM. Interaction between antiretroviral drugs and acenocoumarol. Antiviral therapy 2011; 16:249-252.
  27. Knysz B, Szymanek A, Gabryś T, Siorowski J, Gładysz A. Therapeutic difficulties due to drug interactions of protease inhibitors with acenocoumarol in a HIV positive woman with Takayasu syndrome and pregnancy. A case report. HIV and AIDS Review 2010; 9(3): 83–85.
  28. Borrás-Blasco J, Enriquez R, Navarro-Ruiz A, Martinez-Ramirez M, Cabezuelo JB, Gonzalez-Delgado M. Interaction between cyclosporine and acenocoumarol in a patient with nephrotic syndrome. Clin Nephrol. 2001;55(4):338-40.
  29. Monastero R, Camarda R, Camarda C. Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer’s disease. Clin Ther. 2007; 29(12):2706-9. doi: 10.1016/j.clinthera.2007.12.026.
  30. Pardo A, García-Losa M, Fernández-Pavón A, del Castillo S, Pascual-García T, García-Méndez E, Dal-Ré R. A placebo-controlled study of interaction between nabumetone and acenocoumarol. Br J Clin Pharmacol. 1999; 47(4):441-4.
  31. (Accessed on 22nd January 2016).
  32. (Accessed on 22nd January 2016).
  33. (Accessed on 22nd January 2016).
  34. (Accessed on 22nd January 2016).
  35. Falk RH. Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol. 2004; 44 (8).
  36. C.Mihalopoulos, PharmD Candidate, 2012.
  37. Teichert M , Visser LE, Uitterlinden AG, Hofman A, Buhre PJ, Straus S, De Smet PA, Stricker BH. Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol. 2011; 72(5): 798–805.
  38. (Accessed on 22nd January 2016).
  39. (Accessed on 22nd January 2016).
  40. (Accessed on 22nd January 2016).
  41. (Accessed on 22nd January 2016).
  42. (Accessed on 22nd January 2016).
  43. Palareti G et al, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy, Lancet. 1996 Aug 17; 348(9025):423-8.
  44. Bán A, Long-term treatment with coumarin preparations in advanced age, Z Gesamte Inn Med. 1984 Dec 15; 39(24):617-20.
  45. Woods A et al, Antithrombotic therapy in children and adolescents, Thromb Res. 1986 May 1; 42(3):289-301.
  46. Afzal Azim et al. Safety and Cost-effectiveness of Acitrom® for DVT Prophylaxis in Critically ill Patients Requiring Prolonged Mechanical Ventilation – A Preliminary Experience. J Anaesth Clin Pharmacol 2010; 26(3): 360-362.
  47. Barcellona D et al, Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost. 1998 Dec;80(6):899-902.
  48. Van Leeuwen Y et al, The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon., Thromb Res. 2008;123(2):225-30.
  49. Kaboli P, Henderson MC and White RH, DVT prophylaxis and anticoagulation in the surgical patient, Med Clin N Am, 2003; 87: 77-110.
  50. Azim A et al, Safety and Cost-effectiveness of Acitrom® for DVT Prophylaxis in Critically ill Patients Requiring Prolonged Mechanical Ventilation – A Preliminary Experience, J Anaesth Clin Pharmacol 2010; 26(3): 360-62.
  51. Lensing AWA, Efficacy and safety of various Vitamin K antagonists for the treatment of symptomatic venous thromboembolism, Hematology Meeting Reports
    2008; 2(1): 11-12.
  52. Marusic S et al, Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report, Eur J Clin Pharmacol 2009; 65(12): 1265-66.
  53. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126: 401‐428.
  54. International AnticoagulaNT Review Group, Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction, Lancet, 1970; 295: 203-209.
  55. Sixty Plus Reinfarction Study Research Group , A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction, Lancet, 1980; 316: 989-94.
  56. Hurtado L, et al, Hospital course of acute myocardial infarction treated with or without anticoagulants, Arch Inst Cardiol Mex. 1984 Sep-Oct;54(5):463-70.
  57. Smith Jr SC, Allen J, Blair SN et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update.
    J Am Coll Cardiol. 2006;47(10):2130-2139.
  58. Mulder BJ et al, Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting., Eur Heart J. 1994 Aug;15(8):1129-34.
  59. Palomeras E et al, Oral anticoagulation in the secondary prevention of cerebrovascular disease. Long-term follow-up of 169 patients, Rev Neurol. 1998 Nov; 27(159):772-6.
  60. Bogousslavsky and Regli F, Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke, Acta Neurol Scand. 1985 Jun;71(6):464-71.
  61. Dettori AG et al, Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group, Angiology 1989; 40(4 Pt 1):237-48.
  62. European Heart Rhythm Association. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012.
  63. Authors/Task Force Members, Camm AJ, Lip GY, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747. doi:10.1093/eurheartj/ehs253. Epub 2012 Aug 24.
  64. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA.2001;285:2864-70.
  65. Van Walraven WC, Hart RJ, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003; 163:936-43.
  66. European Heart Rhythm Association; Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
  67. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user‐friendly score (HAS‐BLED) to assess 1 ‐ year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138(5):1093–1100. Epub 2010 Mar 18.
  68. Blanch P et al, Use of Oral Anticoagulants in Patients Discharged With Atrial Fibrillation in 2000, Rev Esp Cardiol 2003;56(11):1057-63.
  69. Rewiuk K et al, Knowledge of antithrombotic prophylaxis among patients with atrial fibrillation, Cardiology Journal, 2007; 14: 44-49.
  70. Pengo V et al, Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment, Thromb Haemost. 2003 Apr; 89(4):760-4.
  71. Zharkova TV et al, Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation, Kardiologiia. 2007; 47(6):31-6.
  72. Attie F et al, Late results of mitral valve replacement with the Björk-Shiley prosthesis in children under 16 years of age, J Thorac Cardiovasc Surg. 1986 May; 91(5):754-8.
  73. Altman R et al, Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1991 Mar; 101(3):427-31.
  74. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted‐dose warfarin versus lowintensity, fixed‐dose warfarin plus aspirin for high‐risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
  75. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114(5 Suppl):445S-469S.
  76. Arun Gogna, Sandeep Arun. Oral Anticoagulation in Clinical Practice. JIACM 2005; 6 (1): 53-66.
  77. Holbrook A, Schulman S, Daniel M, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence based clinical practice guidelines. Chest. 2012;141(Suppl):e44S–e88S.
  78. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15–20.
  79. Warfarin therapy management. Guidelines and Protocols advisory Committee. British Columbia Medical Association. Available at:
  80. THINRS: Home INR monitoring as effective as clinic-based care. Available at:
  81. Simmons BJ, Jenner KM, Delate T, et al. Pilot study of a novel patient self-management program of warfarin therapy using vein puncture acquired international normalized ratio monitoring. Pharmacotehrapy. 2012 Epub ahead of print. Doi:10. 1002/phar.1139.
  82. Available at:
  83. Goldstein JH, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleveland Clinical Journal of Medicine. 2010;77:791-799.
  84. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation. 2012;125:165–170.
  85. Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism. Curr Med Res Opin. 2010;26:2465–2473.
  86. Robert-Ebadi H, Gal GL, Righini M. Use of anticoagulants in elderly patients: Practical recommendations. Clin IntervAging. 2009;4:165–177.
  87. Grand’Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs. 2005;5:291–305.
  88. Calvo-Romero JM, Lima-Rodriguez EM. Prolonged acenocoumarol treatment in patients with venous thromboembolic disease from a rural area. South Med J. 2007;100:725.
  89. Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32:3147–3197.
  90. Vasu S, Stergiopoulos K. Valvular heart disease in pregnancy. Hellenic J Cardiol. 2009;50:498–510.
  91. Management of pregnant women with artificial heart valves: Inconsistency in ESC publications. Available at:
    Assessed on: 5 October 2012.
  92. Pieper PG, Balci A, Van Dijk AP. Pregnancy in women with prosthetic heart valves. Neth Heart J. 2008;16(12):406-411.
  93. Stefanidis K, Papoutsis D, Daskalakis G, et al. Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: A case report. Fetal Diagn Ther.
  94. Duhl AJ, Paidas MJ, Ural SH, et al. Antithrombotic therapy and pregnancy: Consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007;197(5):457.e1–457.e21.
  95. Guidelines on the diagnosis and management of acute pulmonary embolism.The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) European. Heart J. 2008;29:2276–2315.
  96. Michota F, Merli G. Anticoagulation in special patient populations: Are special dosing considerations required? Cleve Clin J Med. 2005;72(Suppl 1):S37–S42.
  97. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123–2129.
  98. Pengo V, Noventa F, Denas G, et al. Long term use of vitamin K antagonists and incidence of cancer: A population based study. Blood. 2011;117:1707–1709.
  99. Cicco MD, Matovic M, Balestreri B, et al. Early and short term acenocoumarine or dalteparin for the prevention of central vein catheer related thrombosis in cancer patients: A randomized controlled study based on serial venographies. Ann Oncol. 2009;20:1936–1942.
  100. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58:470–484.
  101. Nutescu EA. Clinical applications of novel anticoagulants in high-risk patient populations: Obesity, renal insufficiency, and pregnancy. Frontiers in Hematology. 2004;2:4–6.
  102. Chronic Kidney Disease and Atrial Fibrillation: A Contemporary Overview. Available at:
    Assessed on: 5 October 2012.
  103. FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant dabigatran. Available at:
    IND2216428 11 JAN 2022
  104. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 Guideline update for coronary artery bypass graft surgery: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to update the 1999 guidelines for coronary artery bypass graft surgery). Circulation. 2004;110:1168-1176.
  105. McKenzie JL, Douglas G, Bazargan A. Perioperative management of anticoagulation in elective surgery. ANZ Journal of Surgery. 2013. doi: 10.1111/ans.12170.
  106. Mydin M, Dimitrakakis G, Younis J, et al. Optimal thromboprophylaxis following biprosthetic aortic valve replacement: still a matter of debate? Interactive Cardiovascular and Thoracic Surgery. 2012;15:109-114.